X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs NOVARTIS - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD NOVARTIS STRIDES SHASUN LTD/
NOVARTIS
 
P/E (TTM) x 42.6 331.2 12.9% View Chart
P/BV x 1.1 36.7 2.9% View Chart
Dividend Yield % 0.9 1.2 75.1%  

Financials

 STRIDES SHASUN LTD   NOVARTIS
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
NOVARTIS
Mar-18
STRIDES SHASUN LTD/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,275758 168.2%   
Low Rs918579 158.5%   
Sales per share (Unadj.) Rs389.6228.4 170.6%  
Earnings per share (Unadj.) Rs28.031.7 88.1%  
Cash flow per share (Unadj.) Rs48.932.8 149.2%  
Dividends per share (Unadj.) Rs4.5010.00 45.0%  
Dividend yield (eoy) %0.41.5 27.4%  
Book value per share (Unadj.) Rs303.1297.1 102.0%  
Shares outstanding (eoy) m89.4224.69 362.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.82.9 96.1%   
Avg P/E ratio x39.221.1 186.1%  
P/CF ratio (eoy) x22.420.4 109.9%  
Price / Book Value ratio x3.62.2 160.8%  
Dividend payout %16.131.5 51.1%   
Avg Mkt Cap Rs m98,03616,505 594.0%   
No. of employees `0005.80.7 868.3%   
Total wages/salary Rs m5,8811,445 406.9%   
Avg. sales/employee Rs Th6,005.98,441.3 71.1%   
Avg. wages/employee Rs Th1,014.02,163.6 46.9%   
Avg. net profit/employee Rs Th431.21,173.1 36.8%   
INCOME DATA
Net Sales Rs m34,8345,639 617.8%  
Other income Rs m1,6861,718 98.1%   
Total revenues Rs m36,5207,357 496.4%   
Gross profit Rs m6,428-63 -10,284.8%  
Depreciation Rs m1,87225 7,397.2%   
Interest Rs m2,26955 4,103.6%   
Profit before tax Rs m3,9731,575 252.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,0060-   
Tax Rs m470792 59.4%   
Profit after tax Rs m2,501784 319.2%  
Gross profit margin %18.5-1.1 -1,664.9%  
Effective tax rate %11.850.3 23.5%   
Net profit margin %7.213.9 51.7%  
BALANCE SHEET DATA
Current assets Rs m38,1659,522 400.8%   
Current liabilities Rs m30,4023,296 922.4%   
Net working cap to sales %22.3110.4 20.2%  
Current ratio x1.32.9 43.5%  
Inventory Days Days7737 211.2%  
Debtors Days Days10428 367.6%  
Net fixed assets Rs m37,63946 81,824.3%   
Share capital Rs m894123 724.6%   
"Free" reserves Rs m26,2107,213 363.4%   
Net worth Rs m27,1057,336 369.5%   
Long term debt Rs m16,3770-   
Total assets Rs m81,16811,105 730.9%  
Interest coverage x2.829.5 9.3%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.5 84.5%   
Return on assets %5.97.6 77.8%  
Return on equity %9.210.7 86.4%  
Return on capital %12.122.2 54.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m13,46561 22,219.6%   
Fx outflow Rs m4,0763,630 112.3%   
Net fx Rs m9,389-3,570 -263.0%   
CASH FLOW
From Operations Rs m2,8811,610 179.0%  
From Investments Rs m-7,051687 -1,026.4%  
From Financial Activity Rs m3,382-2,677 -126.4%  
Net Cashflow Rs m-788-380 207.5%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 37.8 2.0 1,890.0%  
FIIs % 8.6 1.6 537.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 21.5 120.5%  
Shareholders   56,241 41,647 135.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   ALEMBIC LTD  SUN PHARMA  IPCA LABS  FDC LTD.  AUROBINDO PHARMA  

Compare STRIDES SHASUN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Lower; FMCG & IT Stocks Witness Losses(Closing)

After opening the day on a positive note today, Indian share markets witnessed losses thereafter and ended their trading session marginally lower.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Sep 26, 2018 03:37 PM

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD - CIPLA COMPARISON

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS